Survodutide GLP-1 receptor dual agonist to be assessed in three global Phase III studies for obesity
Boehringer Ingelheim will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III studies for...
top of page
Browse by category
Search
Skooterama launches a bariatric scooters
Skooterama, a provider of mobility solutions, has expanded its product line with the launch of Bariatric Scooters. According to the...
Aardvark Therapeutics gains Rare Pediatric Disease Designation for Prader-Willi Syndrome
The FDA has granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare...
MBX Biosciences gains FDA clearance to study MBX 1416 for post-bariatric hypoglycaemia
MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide (PEP) therapeutics to treat an array...
New survey reveals how surgeons define innovation in real life
A recent survey carried out by Sermo, a physician-only online community of more than 1.3 million healthcare providers globally,...
First subject receives DR10624 for the treatment of obesity and hypertriglyceridemia
Zhejiang Doer Biologics, a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...
MEDICAL IP gains FDA approval for DeepCatch AI software for whole-body composition CT quantification
MEDICAL IP, an AI-based digital twin company, has revealed its CT-based automatic body composition analysis AI software, DeepCatch, has...
GI Dynamics rebrands as Morphic Medical and reintroduces RESET, formerly the EndoBarrier
GI Dynamics, the creator of the EndoBarrier device designed to target the underlying cause of type 2 diabetes, has announced it has...
Phenomix Sciences launches MyPhenome Hungry Brain phenotype swab test
Phenomix Sciences has launched its second of its gut-brain axis phenotyping test, MyPhenome Hungry Brain, new buccal swab test that...
Positive results for mizagliflozin in post-bariatric hypoglyceamia patients
Vogenx has announced positive results from its VGX 001-011 study, a phase 2 multi-centre, randomised, sequential crossover, single...
Browse by tag
bottom of page